摘要
目的探讨大肠埃希菌尿路感染的临床发病特点及对抗生素的耐药情况。方法对2001年1月至2005年12月尿路感染患者尿培养分离出的156株大肠埃希菌进行耐药性分析,用纸片扩散法表型确证试验检测ESBLs。结果大肠埃希菌耐药率最低的抗菌药物是亚胺培南、美罗培南、头孢哌酮/舒巴坦、氧哌嗪青霉素/他唑巴坦,分别为1.28%、1.92%、3.21%、5.13%;对氨苄西林、氟喹诺酮类、庆大霉素、复方新诺明耐药率均>70%。产ESBLs的大肠埃希菌对亚胺培南、美罗培南、头孢哌酮/舒巴坦、氧哌嗪青霉素/他唑巴坦的耐药性均<10%,对氨苄西林、头孢菌素类、氟喹诺酮类均表现出很强的耐药性。结论治疗大肠埃希菌感染时,需根据药敏结果选用碳青霉烯类、β-内酰胺类/β-内酰胺酶抑制剂等。
Objective To investigate the clinical characteristic and antimierobial resistance in patients with urinary tract infected by Eseherichia coll. Methods Drug resistances of 156 Eseheriehia eoli strains collected from the urinary tract infection patients from January 2001 to December 2005 were analyzed. And the extended spectrum β-1aetamase（ESBLs） were identified by disc agar diffusion method. Results The drug resistance of Escherichia coli isolated from urine to Imipenem, Meropenem, Cefoperazone/Sulbactam, Piperaeillin/tazobaetam were the least, it were 1.28%, 1.92% ,3.21% and 5.13% respectively, while the ESBLs-produeing Escherichia coli were all less than 10.0% ;the drug resistance of Escherichia coli isolates to Ampieillin, Quinolones, Gentamiein and TMP-SMZ were higher than 70%, and all were highly resistant to Ampieillin, Cephalosporins, Quinolones. Conclusion We should choose earbopenems,β-1aetam/β-1aetamase inhibitor combinations ,etc, on the basis of microbial sensitivity.
出处
《中国微生态学杂志》
CAS
CSCD
2007年第5期461-462,共2页
Chinese Journal of Microecology
关键词
大肠埃希菌
尿路感染
耐药性
产超广谱Β-内酰胺酶
Eseherichia eoli
Urinary tract infection
Drug resistance
ESBLs-produeing bacteria
